← Human Trials & Peer-Reviewed Studies
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on the Effect of a Dietary Supplement Containing Dry Artichoke and Bergamot Extracts on Metabolic and Vascular Risk Factors in Individuals with Suboptimal Cholesterol Levels.
Plain-language guide to PMID 38892519 (2024): double-blind randomized controlled trial of Copper (Supplement) in 90 individuals.
Key Facts
- PMID
- 38892519
- Journal
- Nutrients
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Fogacci F et al. (7 authors)
- DOI
- 10.3390/nu16111587
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as a randomized controlled trial.
The aim of this study was to assess whether dietary supplementation with a nutraceutical blend comprising extracts of bergamot and artichoke-both standardized in their characteristic polyphenolic fractions-could positively affect serum lipid concentration and insulin sensitivity, high-sensitivity C-reactive protein (hs-CRP), and indexes of non-alcoholic fatty liver disease (NAFLD) in 90 healthy individuals with suboptimal cholesterol levels.
Why It Was Studied
Participants were randomly allocated to treatment with a pill of either active treatment or placebo.
Who Took Part
According to the abstract, 90 individuals were involved.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.
Neither the individuals nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.
What Was Measured
Topics PubMed links to this paper include Cynara scolymus, Dietary Supplements, Plant Extracts, Non-alcoholic Fatty Liver Disease, Cholesterol, C-Reactive Protein and Insulin Resistance.
Author keywords: artichoke, bergamot and nutraceutical compound.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 90 individuals.
The publication is from 2024 (Nutrients), a journal based in Switzerland.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.